BEACON EMR HIPAA Disclaimer Site Map Social Media
BayCare Health System
Community Benefit Financial Assistance Policy Quality Report Card Health Library News Dr.BayCare Find Us
Services Hospitals Find A Doctor Classes & Events About Us Careers Contact Us Get E-Newsletter
HealthDay Daily Newsfeed
 Back  Back


May We Help You?
 

Call 1-877-692-2922
Monday-Friday, 8am to 5pm

Persons with hearing and speech disabilities can reach the above number through TDD and other specialized equipment by calling the Florida Relay Service at 711.

Contact Us
Send 
e-mail
Search jobs


Decrease (-) Restore Default Increase (+) Font Size
Print    Email
Print this page     Email to a friend

FDA Approves 1st in New Class of Type 2 Diabetes Drugs

Invokana works by blocking reabsorption of glucose in body

FRIDAY, March 29 (HealthDay News) -- The first in a new class of type 2 diabetes drugs was approved Friday by the U.S. Food and Drug Administration.

Invokana (canaglifozin) tablets are to be taken, in tandem with a healthy diet and exercise, to improve blood sugar control in adults with type 2 diabetes.

Invokana belongs to a class of drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It works by blocking the reabsorption of glucose (sugar) by the kidney and increasing glucose excretions in urine, the FDA said in a news release.

"We continue to advance innovation with the approval of new drug classes that provide additional treatment options for chronic conditions that impact public health," Dr. Mary Parks, director of the division of metabolism and endocrinology products in the FDA's Center for Drug Evaluation and Research, said in the news release.

About 24 million Americans have type 2 diabetes, and it accounts for more than 90 percent of diabetes cases diagnosed in the United States, the FDA said. If blood sugar levels are not carefully controlled, there is an increased risk for serious complications, including heart disease, blindness, and nerve and kidney damage, the agency added.

The FDA approval is based on the findings of nine clinical trials involving more than 10,000 patients. Patients who took the drug showed improvement in hemoglobin A1c levels (a measure of blood sugar control) and fasting blood sugar levels.

Invokana should not be used by people with type 1 diabetes or people with type 2 diabetes who have increased ketones in their blood or urine (diabetic ketoacidosis), severe kidney disease, kidney failure or who are on dialysis, the FDA said.

The agency told drug maker Janssen Pharmaceuticals that it must conduct five post-approval studies of the drug to determine the risk of problems such as heart disease, cancer, pancreatitis, liver abnormalities and pregnancy complications.

The most common side effects of Invokana are vaginal yeast infections and urinary tract infections. It may also cause dizziness and fainting.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about type 2 diabetes.


SOURCE: U.S. Food and Drug Administration, news release, March 29, 2013

Health News Copyright © 2013 HealthDay. All rights reserved.


Serving The Tampa Bay Area © Copyright 2014 BayCare Health System